See more : Artefact SA (ALATF.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Vivos Inc. (RDGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vivos Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Canature Health Technology Co., Ltd. (300272.SZ) Income Statement Analysis – Financial Results
- Porsche Automobil Holding SE (POAHF) Income Statement Analysis – Financial Results
- Vertex Securities Limited (VERTEX.BO) Income Statement Analysis – Financial Results
- TT Electronics plc (TTG.L) Income Statement Analysis – Financial Results
- LTC Properties, Inc. (LTC) Income Statement Analysis – Financial Results
Vivos Inc. (RDGL)
About Vivos Inc.
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.50K | 36.50K | 14.89K | 7.00K | 9.50K | 0.00 | 4.05K | 8.11K | 24.11K | 24.11K | 140.60K | 247.97K | 393.60K | 360.61K | 320.36K | 268.24K | 130.06K |
| Cost of Revenue | 25.54K | 28.78K | 12.00K | 5.61K | 6.03K | 0.00 | 1.47K | 2.95K | 474.00 | 1.10K | 105.33K | 72.82K | 64.04K | 70.13K | 125.69K | 155.46K | 55.84K |
| Gross Profit | -6.04K | 7.72K | 2.89K | 1.39K | 3.47K | 0.00 | 2.58K | 5.16K | 23.63K | 23.00K | 35.27K | 175.15K | 329.56K | 290.48K | 194.68K | 112.79K | 74.21K |
| Gross Profit Ratio | -30.95% | 21.15% | 19.39% | 19.89% | 36.55% | 0.00% | 63.67% | 63.65% | 98.03% | 95.42% | 25.09% | 70.63% | 83.73% | 80.55% | 60.77% | 42.05% | 57.06% |
| Research & Development | 732.70K | 343.80K | 286.85K | 84.67K | 67.58K | 104.21K | 203.04K | 328.03K | 149.65K | 44.27K | 416.16K | 973.61K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.77M | 2.18M | 2.22M | 589.25K | 1.27M | 2.37M | 2.30M | 3.83M | 2.45M | 1.96M | 3.40M | 5.54M | 2.22M | 2.89M | 1.70M | 2.37M | 933.95K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.50K | 111.66K | 284.14K | 0.00 | 1.30K | 9.91K | 18.31K | 58.88K | 29.07K | 6.63K | 39.35K | 2.39K |
| SG&A | 1.77M | 2.18M | 2.22M | 589.25K | 1.27M | 2.39M | 2.42M | 4.11M | 2.45M | 1.97M | 3.41M | 5.56M | 2.28M | 2.92M | 1.70M | 2.41M | 936.33K |
| Other Expenses | 0.00 | 0.00 | 2.50M | 3.00K | 0.00 | -17.58K | -575.01K | 2.95K | 5.67K | 11.99K | 208.63K | 483.20K | 609.99K | 945.73K | 1.04M | 3.65M | 1.73M |
| Operating Expenses | 2.79M | 2.53M | 2.50M | 673.91K | 1.33M | 2.47M | 2.62M | 4.44M | 2.60M | 1.98M | 3.61M | 6.05M | 2.89M | 3.87M | 2.74M | 6.05M | 2.66M |
| Cost & Expenses | 2.81M | 2.55M | 2.52M | 679.52K | 1.34M | 2.47M | 2.62M | 4.44M | 2.60M | 1.98M | 3.72M | 6.12M | 2.96M | 3.94M | 2.87M | 6.21M | 2.72M |
| Interest Income | 49.58K | 0.00 | 25.38K | 287.47K | 261.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 599.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 25.38K | 287.47K | 261.37K | 5.65M | 3.90M | 6.26M | 2.66M | 2.46M | 1.60M | 1.10M | 408.47K | 860.25K | 839.63K | 219.45K | 238.98K |
| Depreciation & Amortization | 0.00 | 2.52M | 2.50M | 672.52K | 1.33M | 1.47K | 1.47K | 2.95K | 5.67K | 11.99K | 208.63K | 483.20K | 546.39K | 545.19K | 562.67K | 1.53M | 1.16M |
| EBITDA | -2.79M | 0.00 | -2.50M | -669.52K | -18.74K | -2.49M | -2.51M | -3.59M | 8.90M | -15.64M | -1.66M | -7.00M | -1.79M | -2.65M | -2.59M | -4.41M | -1.47M |
| EBITDA Ratio | -14,323.83% | -6,898.13% | -16,805.25% | -9,564.59% | -13,999.78% | 0.00% | -64,515.07% | -54,680.85% | -10,668.40% | -8,059.69% | -2,397.52% | -2,172.66% | -512.06% | -945.64% | -432.09% | -1,643.33% | -1,101.27% |
| Operating Income | -2.79M | -2.52M | -2.50M | -672.52K | -1.33M | -2.49M | -2.62M | -4.44M | -2.58M | -1.96M | -3.58M | -5.87M | -2.56M | -3.73M | -2.55M | -5.94M | -2.59M |
| Operating Income Ratio | -14,323.83% | -6,898.13% | -16,805.25% | -9,607.44% | -13,999.78% | 0.00% | -64,551.41% | -54,717.19% | -10,691.93% | -8,109.43% | -2,545.90% | -2,367.52% | -650.88% | -1,033.06% | -795.86% | -2,214.16% | -1,991.78% |
| Total Other Income/Expenses | -101.61K | 47.59K | -25.97K | -284.47K | -280.12K | -5.21M | -3.80M | -5.42M | 8.27M | -16.15M | 108.81K | -2.72M | -187.75K | -329.69K | -1.44M | -374.91K | -278.98K |
| Income Before Tax | -2.89M | -2.47M | -2.53M | -956.99K | -1.61M | -7.70M | -6.42M | -9.85M | 6.23M | -18.11M | -3.47M | -8.59M | -2.75M | -4.06M | -3.99M | -6.16M | -2.87M |
| Income Before Tax Ratio | -14,844.89% | -6,767.75% | -16,979.69% | -13,671.31% | -16,948.39% | 0.00% | -158,330.71% | -121,545.33% | 25,853.19% | -75,114.92% | -2,468.52% | -3,462.65% | -698.58% | -1,124.48% | -1,246.08% | -2,295.97% | -2,206.29% |
| Income Tax Expense | 0.00 | -47.59K | 25.38K | 287.47K | 261.37K | 5.21M | 3.90M | 6.26M | 2.66M | 2.46M | 1.60M | 1.10M | 408.47K | 479.69K | 1.44M | 0.00 | 238.98K |
| Net Income | -2.89M | -2.42M | -2.55M | -1.24M | -1.87M | -7.70M | -6.42M | -9.85M | 6.23M | -18.11M | -3.47M | -8.59M | -2.75M | -4.06M | -3.99M | -6.16M | -2.87M |
| Net Income Ratio | -14,844.89% | -6,637.37% | -17,150.14% | -17,778.04% | -19,699.69% | 0.00% | -158,330.71% | -121,545.33% | 25,853.19% | -75,114.92% | -2,468.52% | -3,462.65% | -698.58% | -1,124.48% | -1,246.08% | -2,295.97% | -2,206.29% |
| EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.14 | -1.06 | -3.67 | 2.72 | -45.38 | -27.58 | -90.77 | -31.72 | -57.75 | -66.30 | -141.80 | -79.86 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.14 | -1.06 | -3.67 | 2.72 | -45.38 | -27.58 | -90.77 | -31.72 | -57.75 | -66.30 | -141.80 | -79.86 |
| Weighted Avg Shares Out | 368.81M | 351.43M | 325.85M | 222.80M | 175.20M | 55.50M | 6.05M | 2.69M | 2.31M | 399.09K | 125.86K | 94.59K | 86.69K | 70.22K | 60.21K | 43.43K | 35.93K |
| Weighted Avg Shares Out (Dil) | 368.81M | 351.43M | 325.85M | 222.80M | 175.20M | 55.50M | 6.05M | 2.69M | 2.31M | 399.09K | 125.86K | 94.59K | 86.69K | 70.22K | 60.21K | 43.43K | 35.93K |
Vivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3
Vivos Therapeutics (NASDAQ:VVOS), a medical technology targeting sleep issues such as obstructive sleep apnea (OSA) and snoring, had a strong third quarter marked by higher revenue and reduced operating expenses. Revenue increased 17% year-over-year to $3.9 million compared to $3.3 million...
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call
LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including...
Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM
Richland WA N, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Certifies new clinic for IsoPet therapy.
Vivos Therapeutics wins approval for streamlined insurance reimbursement for sleep apnea treatment
Vivos Therapeutics (NASDAQ:VVOS) announced that the American Medical Association (AMA) has granted new CPT codes for the company's Vivos CARE oral medical devices. Effective January 1, 2025, these codes will streamline insurance coverage and reimbursement for Vivos' devices, designed to...
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults...
Vivos Therapeutics raises $4.3 from institutional investors
Vivos Therapeutics (NASDAQ:VVOS) announced that it has entered into definitive purchase agreements with institutional investors to raise proceeds of $4.3 million through the issuance and sale of an aggregate of 1,363,812 shares at $3.15 each. The company said that no...
Vivos Therapeutics' oral device approved by FDA for pediatric sleep apnea treatment
Vivos Therapeutics (NASDAQ:VVOS) announced that it has received US Food and Drug Administration (FDA) approval to treat moderate to severe obstructive sleep apnea (OSA) in children aged 6 to 17 using its proprietary oral medical device. This non-invasive, orthodontic-based solution offers...
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model
Vivos Therapeutics boosts Q2 revenue, cuts operating losses amid new strategic partnerships
Vivos Therapeutics (NASDAQ:VVOS) reported solid financial numbers for the second quarter of 2024 with a 19% increase in revenue. The company reported a revenue of $4.1 million compared to the $3.4 million reported in the same quarter of 2023, which...
Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo.,...
Source: https://incomestatements.info
Category: Stock Reports